Tema Etfs LLC Takes $1.13 Million Position in Merck & Co., Inc. (NYSE:MRK)

Tema Etfs LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,342 shares of the company’s stock, valued at approximately $1,128,000.

Several other institutional investors have also bought and sold shares of MRK. Norges Bank bought a new stake in Merck & Co., Inc. during the fourth quarter worth $3,479,799,000. Bank of New York Mellon Corp grew its stake in Merck & Co., Inc. by 29.7% in the 4th quarter. Bank of New York Mellon Corp now owns 24,213,537 shares of the company’s stock valued at $2,408,763,000 after purchasing an additional 5,550,824 shares during the period. Wellington Management Group LLP grew its stake in Merck & Co., Inc. by 6.5% in the 4th quarter. Wellington Management Group LLP now owns 80,742,030 shares of the company’s stock valued at $8,032,217,000 after purchasing an additional 4,932,647 shares during the period. Northern Trust Corp grew its stake in Merck & Co., Inc. by 16.8% in the 4th quarter. Northern Trust Corp now owns 31,377,107 shares of the company’s stock valued at $3,121,395,000 after purchasing an additional 4,511,742 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Merck & Co., Inc. by 63.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 11,577,535 shares of the company’s stock valued at $1,151,642,000 after purchasing an additional 4,480,007 shares during the period. Institutional investors own 76.07% of the company’s stock.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, SVP Dalton E. Smart III sold 4,262 shares of the firm’s stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $82.76, for a total value of $352,723.12. Following the sale, the senior vice president now owns 7,778 shares of the company’s stock, valued at $643,707.28. This trade represents a 35.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Morgan Stanley reduced their price objective on Merck & Co., Inc. from $113.00 to $106.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. StockNews.com downgraded Merck & Co., Inc. from a “strong-buy” rating to a “buy” rating in a research note on Friday, April 25th. Cantor Fitzgerald assumed coverage on Merck & Co., Inc. in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $85.00 price objective for the company. Guggenheim restated a “buy” rating and issued a $115.00 price objective on shares of Merck & Co., Inc. in a research note on Thursday, April 17th. Finally, TD Cowen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their price objective for the company from $121.00 to $100.00 in a research note on Monday, February 10th. Thirteen equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $109.19.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $76.08 on Friday. The stock’s 50-day simple moving average is $83.46 and its 200 day simple moving average is $92.24. The stock has a market capitalization of $191.03 billion, a price-to-earnings ratio of 11.30, a price-to-earnings-growth ratio of 0.77 and a beta of 0.43. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $134.63.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, April 24th. The company reported $2.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.06. The business had revenue of $15.53 billion for the quarter, compared to analysts’ expectations of $15.59 billion. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.07 EPS. Research analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. announced that its board has authorized a stock repurchase plan on Tuesday, January 28th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 4.1% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.